Report of Foreign Issuer (6-k)
January 06 2016 - 4:51PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
the Month of January 2016
Commission
File Number 001-33042
Rosetta Genomics Ltd.
(Translation of registrant’s name into English)
10 Plaut Street, Science Park
Rehovot 76706, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Rosetta Genomics Ltd.
On January 6, 2016, Rosetta Genomics Ltd.
(the “Company”) issued a press release announcing the signing of an agreement with Mirna Therapeutics, Inc. for a worldwide
sublicense to the Company’s patents related to therapeutic uses of certain microRNA technologies. The agreement includes
an exclusive sublicense related to Mirna’s MRX34 product candidate, a mimic of naturally occurring microRNA-34 being evaluated
in clinical studies for a variety of cancers. Under the terms of the agreement, the Company will receive an upfront payment of
$1.6 million from Mirna, and is eligible for low single-digit royalties on product sales and potential milestone payments and sublicense
payments. A copy of the press release is filed as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.
The information contained in this Report
(including the exhibit hereto) is hereby incorporated by reference into the Company’s Registration Statements on Form F-3,
File Nos. 333-163063, 333-171203, 333-172655, 333-177670, 333-185338 and 333-207697.
Exhibits
Exhibit
Number |
|
Description of Exhibit |
|
|
|
99.1 |
|
Press Release dated January 6, 2016. |
|
|
|
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ROSETTA GENOMICS LTD. |
|
|
Date: January 6, 2016 |
By: |
/s/ Oded Biran |
|
|
|
|
|
Oded Biran
Chief Legal Officer and Corporate Secretary |
Exhibit 99.1
News Release
Rosetta Genomics
Grants Sublicenses to Mirna Therapeutics
for microRNA-related
Patents for the Development of Oncology Therapeutics
PHILADELPHIA, REHOVOT, Israel (January 6, 2016) –
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today
announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide sublicense to Rosetta’s patents
related to therapeutic uses of certain microRNA technologies. The agreement includes an exclusive sublicense related to Mirna’s
MRX34 product candidate, a mimic of naturally occurring microRNA-34 being evaluated in clinical studies for a variety of cancers.
Under the terms of the agreement, Rosetta Genomics will receive
an upfront payment of $1.6 million from Mirna, and is eligible for low single-digit royalties on product sales and potential milestone
payments and sublicense fees. The sublicensed patents are jointly owned by YEDA Research and Development Company Ltd., the commercial
arm of the Weizmann Institute of Science, and Rosetta Genomics. As such, YEDA is entitled to a portion of these and other proceeds
Rosetta may receive under the agreement with Mirna.
“We are pleased to execute this agreement with Mirna as
it underscores the value of our leading intellectual property position in microRNA technology and represents a new avenue through
which we can create value by leveraging our extensive patent portfolio,” noted Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics. “We look forward to Mirna pursuing the potential of microRNAs as new and effective cancer therapeutics
and believe microRNAs can play an important role in developing treatments for different cancers.”
About Rosetta Genomics
Rosetta develops and commercializes a
full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics
and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies
in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s cancer testing services
are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively.
For more information visit www.rosettagx.com.
Rosetta Genomics Forward-Looking Statement
Disclaimer
Various statements in this release concerning
Rosetta’s future expectations, plans and prospects, including but not limited to statements with respect to the potential
for Rosetta to receive royalties on product sales and milestone payments, and sublicensing fees, and Rosetta’s potential
to create value by leveraging its extensive patent portfolio constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the
"Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2014 as filed
with the Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta
does not assume any obligation to update any forward-looking statements unless required by law.
Rosetta Genomics Contact: |
Rosetta Genomics Investor Contact: |
Ken Berlin, President & CEO |
LHA |
(609) 419-9003 |
Anne Marie Fields |
investors@rosettagenomics.com |
(212) 838-3777 |
|
afields@lhai.com |
# # #
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024